«TableStart:Samples»

|  |  |  |
| --- | --- | --- |
| To: PETER MAC CANCER CENTRE  ST ANDREWS PL  EAST MELBOURNE  VIC 3002 | **Patient**: «patient»  **URN**: «urn»  **DOB**: «dob»  **SEX**: «sex»  **Location**: «location»  **Requester**: «requester» | Sample: «sample»  Ext Ref: «extref»  Collected: «collect\_date»  Received: «rcvd\_date»  Specimen:  Block ID: |
|  |  |  |

**NEXT GENERATION SEQUENCING REPORT** «isdraft»

|  |
| --- |
| **Failed assay due to poor DNA quality in this sample** |

**Clinical indication –**

**Sample type –**

**Estimated tumour burden of sample –**

|  |  |
| --- | --- |
| **ASSAY** | **26-GENE FULL LYMPHOID PANEL** |
| **Genes** | AKT1 (exon 3), BIRC3 (exon 6-9), BRAF (exon 11, 15), BTK (exon 15), CARD11 (exon 4-9), CXCR4 (exon 2), DNTM3A (exon 23), EZH2 (exon 16, 18), FYN (exon 7), FOXO1 (ex 1), IDH1 (exon 4), IDH2 (exon 4), JAK3 (exon 13, 15), KRAS (exon 2-4), MYD88 (exon 5), NOTCH1 (exon 26, 27, 28, 34), NRAS (exon 2-4), PHF6 (exon 7-10), PIK3CA (exon 10, 21), PLCG1 (exon 11), PLCG2 (exon 19, 20, 24), RHOA (exon 2), RUNX1 (exon 4-9), SF3B1 (exon 14-16), STAT3 (exon 21), STAT5B (exon 16), STAT6 (exon 10,13, 16), TP53 (exon 2-11) |

**Method**

DNA is analysed using a custom-designed lymphoid amplicon gene panel (Lymphoid v5.4.2). Samples are uniquely indexed, pooled and sequenced on the Illumina MiSeq using MiSeq v2 chemistry at 2x151bp reads. Alignment, variant calling and annotation are performed using an amplicon-optimised pipeline. Only plausible pathogenic variants passing multiple functional and quality filters and that are present in the “*Genes analysed*” list above are reported. Amplicons with less than 100 aligned reads are not analysed. The technology employed here is not suitable for detecting loss of heterozygosity, copy number variations, gross structural rearrangements, or aneuploidies. At 1000x coverage, this assay has a detection limit of approximately 5%.

Please contact the laboratory on 03 9656 5297 if you wish to discuss this report further.

**Reported by: Dr. Costas Yannakou (Haematology Fellow)**

**Dr. Piers Blombery (Consultant Haematologist)**

**Authorised by: Ms. Michelle McBean**

**Reported:**

*«TableEnd:Samples»*